Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended March 31, 2026
Business Overview: A global developer, manufacturer, and marketer of animal health and mineral nutrition products for food and companion animals, as well as performance products for personal care and industrial chemical industries. The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2026 | Nine Months Ended Mar 31, 2026 |
|---|---|---|
| Net Sales | $383,543 | $1,121,346 |
| Gross Profit | $125,675 | $378,114 |
| Gross Margin | 32.8% | 33.7% |
| Operating Income | $44,653 | $146,239 |
| Net Income | $24,024 | $78,010 |
| Diluted EPS | $0.59 | $1.90 |
| Adjusted EBITDA | $60,801 | $190,723 |
| Cash from Operating Activities | N/A | $44,860 |
| Total Debt (Long-term + Current) | $620,516 (Net of issuance costs) | $620,516 |
| Cash and Short-term Investments | $77,451 | $77,451 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% ($35.7M) for the quarter and 22% ($203.8M) for the nine-month period compared to the prior year. Growth was primarily driven by the Animal Health segment, which saw a 13% quarterly increase and 29% nine-month increase, largely due to the October 2024 acquisition of the Zoetis medicated feed additives portfolio.
- Profitability: Operating income surged 33% ($11.1M) for the quarter and 91% ($69.5M) for the nine-month period. Gross margins expanded 270 basis points (quarterly) and 210 basis points (nine-month) due to favorable product mix, volume increases, and pricing, partially offset by higher input costs.
- Segment Performance:
- Animal Health: Sales up 13% (Q) and 29% (9M). Adjusted EBITDA up 13% (Q) and 41% (9M).
- Mineral Nutrition: Sales up 10% (Q) and 9% (9M). Adjusted EBITDA declined 11% (Q) but rose 5% (9M).
- Performance Products: Sales declined 17% (Q) and 12% (9M) due to lower demand for personal care ingredients. Adjusted EBITDA fell 33% (Q) and 38% (9M).
- Interest Expense: Net interest expense increased 12% ($1.1M) for the quarter and 32% ($8.3M) for the nine months, driven by higher debt balances from the acquisition and the expiration of a favorable interest rate swap.
- Foreign Currency: The company reported a net foreign currency loss of $1.9M for the quarter, compared to a gain of $5.5M in the prior year quarter.
Guidance, Outlook, Risks, and Unusual Items
- Acquisition Integration: The Zoetis acquisition contributed $95.9M in revenue for the quarter and $270.5M for the nine months. Management continues to integrate these assets, which expanded the medicated feed additives portfolio.
- Debt and Liquidity: On April 28, 2026 (subsequent to period end), the company amended its credit agreement to increase revolving credit commitments by $125M to $435M. As of March 31, 2026, $193.2M was available under the revolver. The company remains in compliance with financial covenants.
- Regulatory Risks:
- Carbadox (Mecadox): The FDA has revoked the approved method for detecting carbadox residues. Phibro is defending the product's safety and has filed a lawsuit to invalidate the order. Sales of Mecadox were approximately $22M in the trailing twelve months.
- Brazil Antimicrobials: Brazil's Ministry of Agriculture (MAPA) issued an ordinance prohibiting the use of certain antimicrobials (including virginiamycin) for growth promotion, with an 180-day transition period. Phibro is seeking therapeutic indications for these products.
- Geopolitical Risks: Ongoing conflicts in the Middle East (Israel) and between Russia and Ukraine pose risks to operations, supply chains, and logistics. Israeli facilities represent 17% of consolidated assets and 16% of nine-month net sales.
- Tariff Recovery: Following a Supreme Court ruling in February 2026, the company is pursuing the recovery of previously paid IEEPA tariffs, though the timing and amount of recovery remain uncertain.
- Unusual Items: Adjustments to GAAP net income included acquisition-related costs, "Phibro Forward" initiative costs (consultancy and restructuring), and foreign currency fluctuations.
Investor Verification Checklist
- Acquisition Synergies: Verify the timeline and cost savings realization from the Zoetis acquisition integration.
- Regulatory Outcomes: Monitor the status of the FDA lawsuit regarding carbadox and the approval status of therapeutic indications for virginiamycin in Brazil.
- Debt Servicing: Assess the impact of rising interest rates and the expiration of hedging instruments on future interest expense.
- Geopolitical Exposure: Evaluate the potential operational disruption risks associated with the 17% of assets located in Israel.
- Performance Products Turnaround: Review strategies to reverse the double-digit sales decline in the Performance Products segment.
- Tariff Refunds: Track the administrative process for recovering IEEPA tariffs and the likelihood of recognition in future financial statements.